PerkinElmer
check quantity

AlphaLISA SureFire Ultra STAT1 pS727, 10,000 Assay Points

The AlphaLISA® SureFire® Ultra p-STAT1 (Ser727) assay is a sandwich immunoassay for quantitative detection of phospho-STAT1 (phosphorylated on Ser727) in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
ALSU-PST1-B-HV
100 Assay Points
504.00 USD
 
more
ALSU-PST1-B500
500 Assay Points
1703.00 USD
 
more
ALSU-PST1-B10K
10,000 Assay Points
9400.00 USD
 
more
ALSU-PST1-B50K
50,000 Assay Points
29200.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

The AlphaLISA® SureFire® Ultra p-STAT1 (Ser727) assay is a sandwich immunoassay for quantitative detection of phospho-STAT1 (phosphorylated on Ser727) in cellular lysates using Alpha Technology.

This kit contains reagents to run 100 wells in 96-well format, using a 60 µL reaction volume.

In the AlphaLISA® SureFire® Ultra assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure agent that immobilizes the other antibody, labeled with a CaptSure tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.

AlphaLISA® SureFire® Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

Alpha SureFire® kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • Screening

Specifications

Assay Pathway JAK/STAT
Assay Target STAT1
Assay Target Class Phosphoprotein
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Shipping Condition Blue Ice
Unit Size 10,000 Assay Points
Resources, Events & More
  • All

Application Note

Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA

Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.

PDF 4 MB